Using these LC3B and GATE-16 variants in an in vitro AML model, it became evident that blocking the LIRs of SAR proteins impairs the growth of THP-1 cells and increases their susceptibility to cytarabine treatment. This evidence concerns the gene MAP1LC3B and acute myeloid leukemia.